August 29, 2022

RE: Mavyret® (Glecaprevir/Pibrentasvir) Update

Effective immediately, as part of an initiative by the Oklahoma Health Care Authority (OHCA) to cure hepatitis C virus (HCV) in the SoonerCare population, Mavyret® (glecaprevir/pibrentasvir) is the only preferred direct-acting antiviral (DAA) medication for HCV and is now available without prior authorization (PA). Mavyret® is FDA approved to treat adult and pediatric patients 3 years of age and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). It is also approved to treat HCV GT 1 infection in patients who have been previously treated with a regimen that contained an HCV NS5A inhibitor or an HCV NS3/4A protease inhibitor, but not both. Mavyret® is available as glecaprevir/pibrentasvir 100mg/40mg oral tablets and 50mg/20mg packets of oral pellets.

Pharmacists who may be dispensing Mavyret® should familiarize themselves with Mavyret® prescribing information, including recommended dosing and drug interactions, and patient information which is available on the Mavyret® website, https://www.mavyret.com/. Patients should be monitored for compliance, counseled regarding the importance of compliance and finishing treatment, and reminded that Mavyret® tablets are dosed 3 tablets once daily.

The American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) have developed HCV treatment guidelines available at https://www.hcvguidelines.org/. Prescribers are encouraged to follow the AASLD/IDSA HCV treatment guidelines and Mavyret® prescribing information, in regards to testing for HCV, selecting the appropriate treatment regimen and length of treatment, and monitoring prior to, during, and after completion of therapy. HCV consultation with specialists, continuing medical education (CME), and care management are available on the Hepatitis C TeleECHO virtual learning network through Project ECHO (Extension for Community Health Care Outcomes) at: https://medicine.okstate.edu/echo/hepatitis-c.html. Additional HCV courses with CME are available on the following educational website, which is funded by the CDC: https://www.hepatitisc.uw.edu/.

Mavyret® is the only DAA available without PA. The PA criteria is still effective and PA forms are still required for other DAAs. PA requests for other DAAs will also require a patient-specific, clinically significant reason why the member cannot use Mavyret®. The specific PA requirements are located on the OHCA website at www.oklahoma.gov/ohca/pa in the “Hepatic Disorders” therapeutic category. Initial PA requests for all other DAAs besides Mavyret® must be submitted using 3 PA forms:
1. The medication-specific PA form
2. Hepatitis C Therapy Intent to Treat Contract form (Pharm-28)
3. Hepatitis C Therapy Pharmacy Agreement form (Pharm-29)
Continuation requests (for each refill) must be submitted using the Hepatitis C Therapy Continuation form (Pharm-30). The PA forms are located on the OHCA website at https://oklahoma.gov/ohca/rxforms.

Thank you for the services you provide to Oklahomans insured by SoonerCare!